Composition for treating hyperlipidemia comprising oxyntomodulin derivative

a technology of oxyntomodulin and hyperlipidemia, which is applied in the direction of drug compositions, peptides, metabolic disorders, etc., can solve the problems of increasing the risk of heart disease, fatty liver disease, and low-density cholesterol, so as to reduce the total cholesterol of the blood, increase and reduce the total cholesterol. , the effect of increasing the high-density cholesterol level

Inactive Publication Date: 2015-07-02
HANMI PHARMA
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0172]The oxyntomodulin derivative of the present invention has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and exhibits the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that we

Problems solved by technology

Low-density (LDL) cholesterol is known to be harmful to health, and it is known that an increase in LDL cholesterol increases the risk of heart disease (Assman et al., Am. J. Card, 1996).
In addition, excessive blood lipids are accumulated in liver tissue, and thus can cause fatty liver disease.
However, dietary therapy or excise therapy is difficult to strictly control and perform, and the therapeutic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating hyperlipidemia comprising oxyntomodulin derivative
  • Composition for treating hyperlipidemia comprising oxyntomodulin derivative
  • Composition for treating hyperlipidemia comprising oxyntomodulin derivative

Examples

Experimental program
Comparison scheme
Effect test

example 1

Production for Cell Line for In Vitro Activation

example 1-1

Production of Cell Line Showing cAMP Response to GLP-1

[0184]Using a portion corresponding to the ORF (open reading frame) of cDNA (OriGene Technologies, Inc. USA) of the human GLP-1 receptor gene as a template, PCR was performed using reverse and forward primers including a HindIII cleavage site and an EcoRI cleavage site, respectively, thereby obtaining a PCR product.

Forward primer:(SEQ ID NO: 50)5′-CCCGGCCCCCGCGGCCGCTATTCGAAATAC-3′Reverse primer:(SEQ ID NO: 51)5′-GAACGGTCCGGAGGACGTCGACTCTTAAGATAG-3′

[0185]The PCR product was cloned into the known animal cell expression vector x0GC / dhfr, thereby constructing the recombinant vector x0GC / GLP-1R.

[0186]The recombinant vector x0GC / GLP-1R was introduced into a CHO DG44 cell line, cultured in DMEM / F12 (10% FBS) medium, using lipofectamine (Invitrogene, USA), to obtain a transformant. The transformant was incubated in a selective medium containing 1 mg / mL G418 and 10 nM methotraxate, and monoclonal cell lines were selected therefrom. Then, ...

example 1-2

Production of Cell Line Showing cAMP Response to Glucagon

[0187]Using a portion corresponding to the ORF (open reading frame) of cDNA (OriGene Technologies, Inc. USA) of the human glucagon receptor gene as a template, PCR was performed using reverse and forward primers including an EcoRI cleavage site and a XhoI cleavage site, respectively, thereby obtaining a PCR product.

Forward primer:(SEQ ID NO: 52)5′-CAGCGACACCGACCGTCCCCCCGTACTTAAGGCC-3′Reverse Primer:(SEQ ID NO: 53)5′-CTAACCGACTCTCGGGGAAGACTGAGCTCGCC-3′

[0188]The PCR product was cloned into the known animal cell expression vector x0GC / dhfr, thereby constructing the recombinant vector x0GC / GCGR.

[0189]The recombinant vector x0GC / GCGR was introduced into a CHO DG44 cell line, cultured in DMEM / F12 (10% FBS) medium, using lipofectamine (Invitrogene, USA), to obtain a transformant. The transformant was incubated in a selective medium containing 1 mg / mL G418 and 10 nM methotraxate, and monoclonal cell lines were selected therefrom. Then...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Therapeuticaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.

Description

TECHNICAL FIELD[0001]The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, which comprises an oxyntomodulin derivative as an active ingredient, and to a method for treating hyperlipidemia, fatty liver disease or arteriosclerosis using the composition.BACKGROUND ART[0002]In recent years, in Korea, the intake of fats from foods has increased due to economic growth and the westernization of eating habits, and metabolic diseases such as hyperlipidemia, diabetes, hypertension, arteriosclerosis and fatty liver disease, which are caused by a lack of exercise, have increased.[0003]Hyperlipidemia refers to a condition associated with elevated levels of lipids, such as free cholesterol, cholesterol esters, phospholipids and triglycerides, in blood. Hyperlipidemia can appear in three forms: (1) hypercholesterolemia, (2) hypertriglyceridemia, and (3) combined hyperlipidemia (hypercholesterolemia and hypertriglyceridemi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/26A61K45/06C07K14/78C07K14/76C07K14/605A61K47/48
CPCA61K38/26C07K14/605A61K47/48369A61K47/48284C07K14/76A61K45/06A61K47/48292C07K14/78A61K38/22A61K2300/00A61K47/60A61K47/59A61K47/593A61K47/643A61K47/6435A61K47/68A61K47/6811A61P1/16A61P3/00A61P3/04A61P31/14A61P31/20A61P3/06A61P43/00A61P9/10A61P3/10A61K38/16C07K19/00
Inventor JUNG, SUNG YOUBKIM, JIN-SUNJANG, MYUNG HYUNLEE, SANG HYUNCHOI, IN YOUNGKWON, SE CHANG
Owner HANMI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap